by | Aug 19, 2024 | Publications
EJHaem. 2024 Jun 10;5(4):867-878. doi: 10.1002/jha2.905. eCollection 2024 Aug. ABSTRACT The incidence of multiple myeloma (MM) has surged globally, particularly in Latin American countries, and is attributable to an aging population and increased life expectancy. This...
by | Aug 15, 2024 | Publications
Front Oncol. 2024 Jul 31;14:1341631. doi: 10.3389/fonc.2024.1341631. eCollection 2024. ABSTRACT INTRODUCTION: Allogeneic hematopoietic cell transplantation (alloHCT) possessed direct cytotoxicity and graft-versus-multiple myeloma effect (GvMM). Growing trials have...
by | Jul 27, 2024 | Publications
Pharmaceuticals (Basel). 2024 Jul 15;17(7):944. doi: 10.3390/ph17070944. ABSTRACT This systematic review examines the available clinical data on CD34+ cell mobilization, collection, and engraftment in multiple myeloma patients treated with the anti-CD38 monoclonal...
by | Jul 22, 2024 | Publications
Ann Med. 2024 Dec;56(1):2380301. doi: 10.1080/07853890.2024.2380301. Epub 2024 Jul 22. ABSTRACT BACKGROUND: Multiple myeloma is a malignant tumour of the blood in which abnormal proliferation of plasma cells leads to bone destruction, renal impairment, anaemia, and...
by | Jul 21, 2024 | Publications
Br J Haematol. 2024 Jul 19. doi: 10.1111/bjh.19627. Online ahead of print. ABSTRACT The growing use of frontline lenalidomide treatment in multiple myeloma (MM) is increasing the proportion of lenalidomide-refractory patients, which may limit the efficacy of...
by | Jul 11, 2024 | Publications
Blood. 2024 Jul 11;144(2):239. doi: 10.1182/blood.2024025274. NO ABSTRACT PMID:38990539 | DOI:10.1182/blood.2024025274
